⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28613782 | 0.76 | LMNA (0.50) | — | |
| SCHEMBL1913169 | 0.73 | — | — | |
| SCHEMBL11236391 | 0.73 | — | — | |
| SCHEMBL7656682 | 0.73 | — | — | |
| SCHEMBL9341264 | 0.71 | — | — | |
| SCHEMBL9624762 | 0.71 | — | — | |
| SCHEMBL20394575 | 0.71 | — | — | |
| SCHEMBL760196 | 0.71 | — | — | |
| SCHEMBL28574828 | 0.71 | — | — | |
| SCHEMBL10883998 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-117957228-A | SGC stimulators | 帝善多制药公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117915917-A | CNS disease treatment using sGC stimulators | 帝善多制药公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-113881728-B | Preparation method of 7-aminomethyl-7-deazaguanine (PreQ 1) | 深圳瑞德林生物技术有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023018155-A1 | COMPOUND HAVING SHP2 PROTEIN DEGRADING ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-02-16 | — | — | WO | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| US-5716964-A | BRAIN DISORDERS; ANTIISCHEMIC AGENTS | G.D. SEARLE & CO. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4600025-A | 2-METHYL-5(HETEROMETHYL)THIAZOLE | GRIGG RONALD E | 1986-07-15 | — | — | US | disclosed |
| EP-0034481-B1 | 2-METHYL-5-THIAZOLE-METHYLAMINE AND CARBOXAMIDE DERIVATIVES | Grigg, Ronald Ernest (GB) | 1984-05-30 | — | — | EP | disclosed |